StreetInsider.com News Articles

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

BEIJING, SHANGHAI and BOSTON, March 10, 2026 /PRNewswire/ -- Jacobio Pharma(HKEX: 1167) today announced its annual results for the year ended Dec. 31, 2025, and provided updates on its key pipeline programs.

During 2025, the company achieved several key advancements in KRAS-targeted therapy and innovative ADC platforms, including the approval and inclusion of the KRAS G12C inhibitor glecirasib in China into the National Reimbursement Drug

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

Jacobio Announces 2025 Annual Results

Tue, 10 Mar 2026 11:30:00 -0400

First Commercial Product Glecirasib Approved and Added to China's NRDL

pan-KRAS and Innovative ADC Pipeline Continue to Advance

Jacobio Pharma licenses cancer drug to AstraZeneca for $2 billion

Sun, 21 Dec 2025 07:15:17 -0400

Jacobio Pharma Group Co. (HKEX: 1167) announced it has entered a licensing agreement with AstraZeneca PLC for its Pan-KRAS inhibitor JAB-23E73, according to a press release statement.

Under the agreement, AstraZeneca receives exclusive development and commercialization rights outside of China, while both companies will jointly develop and commercialize the drug in China. Jacobio will receive an upfront payment of $100 million and is eligible for additional development and commercial milestone payments of up to $1.915 billion, plus tiered royalties on net sales outside of China.

AstraZeneca will handle all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China. The

Jacobio Pharma licenses cancer drug to AstraZeneca for $2 billion

Sun, 21 Dec 2025 07:15:17 -0400

Jacobio Pharma Group Co. (HKEX: 1167) announced it has entered a licensing agreement with AstraZeneca PLC for its Pan-KRAS inhibitor JAB-23E73, according to a press release statement.

AstraZeneca will handle all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China. The

Jacobio Pharma licenses cancer drug to AstraZeneca for $2 billion

Sun, 21 Dec 2025 07:15:17 -0400

Jacobio Pharma Group Co. (HKEX: 1167) announced it has entered a licensing agreement with AstraZeneca PLC for its Pan-KRAS inhibitor JAB-23E73, according to a press release statement.

AstraZeneca will handle all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China. The

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China.

Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Sun, 21 Dec 2025 07:15:00 -0400

Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference